Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Agents | 171 | 2024 | 2406 | 15.360 |
Why?
|
Neoplasms | 194 | 2024 | 3009 | 14.400 |
Why?
|
Pharmacogenetics | 76 | 2024 | 441 | 10.000 |
Why?
|
Glucuronosyltransferase | 50 | 2015 | 185 | 6.560 |
Why?
|
Camptothecin | 53 | 2020 | 191 | 6.260 |
Why?
|
Antineoplastic Agents, Phytogenic | 45 | 2014 | 277 | 4.640 |
Why?
|
Clinical Trials, Phase II as Topic | 24 | 2022 | 175 | 4.630 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 69 | 2021 | 2536 | 4.580 |
Why?
|
Clinical Trials, Phase I as Topic | 32 | 2022 | 155 | 4.210 |
Why?
|
Humans | 546 | 2024 | 88611 | 3.990 |
Why?
|
Research Design | 31 | 2023 | 594 | 3.810 |
Why?
|
Clinical Trials as Topic | 43 | 2023 | 1142 | 3.760 |
Why?
|
Dose-Response Relationship, Drug | 66 | 2023 | 1945 | 3.360 |
Why?
|
Medical Oncology | 17 | 2022 | 376 | 3.330 |
Why?
|
Drug Approval | 7 | 2024 | 66 | 3.270 |
Why?
|
Maximum Tolerated Dose | 27 | 2023 | 272 | 3.220 |
Why?
|
Pyridines | 19 | 2022 | 316 | 3.210 |
Why?
|
Antibodies, Monoclonal, Humanized | 18 | 2023 | 960 | 2.970 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 13 | 2022 | 201 | 2.700 |
Why?
|
Food-Drug Interactions | 8 | 2017 | 19 | 2.690 |
Why?
|
Lung Neoplasms | 25 | 2023 | 2336 | 2.630 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 18 | 2023 | 1111 | 2.620 |
Why?
|
Protein Kinase Inhibitors | 16 | 2022 | 603 | 2.570 |
Why?
|
Polymorphism, Genetic | 31 | 2021 | 825 | 2.450 |
Why?
|
Benzenesulfonates | 12 | 2012 | 66 | 2.410 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2022 | 837 | 2.400 |
Why?
|
Piperidines | 7 | 2022 | 163 | 2.300 |
Why?
|
Aged | 207 | 2024 | 18932 | 2.230 |
Why?
|
United States Food and Drug Administration | 14 | 2024 | 133 | 2.090 |
Why?
|
Drug Labeling | 9 | 2017 | 41 | 2.080 |
Why?
|
Drug Administration Schedule | 58 | 2020 | 902 | 2.070 |
Why?
|
Adenine | 12 | 2022 | 88 | 2.030 |
Why?
|
Middle Aged | 220 | 2024 | 25699 | 2.020 |
Why?
|
Genotype | 53 | 2022 | 1867 | 1.960 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 5 | 2018 | 119 | 1.900 |
Why?
|
Male | 242 | 2024 | 42012 | 1.900 |
Why?
|
Antimetabolites, Antineoplastic | 14 | 2020 | 237 | 1.880 |
Why?
|
Polymorphism, Single Nucleotide | 36 | 2024 | 2399 | 1.830 |
Why?
|
Drugs, Investigational | 11 | 2018 | 36 | 1.830 |
Why?
|
Enzyme Inhibitors | 13 | 2017 | 646 | 1.820 |
Why?
|
Economics, Pharmaceutical | 3 | 2023 | 10 | 1.810 |
Why?
|
Drug Monitoring | 9 | 2024 | 119 | 1.800 |
Why?
|
Biomarkers, Tumor | 21 | 2024 | 1520 | 1.800 |
Why?
|
Sirolimus | 7 | 2018 | 173 | 1.790 |
Why?
|
Drug Interactions | 24 | 2022 | 248 | 1.790 |
Why?
|
Androstenes | 5 | 2021 | 43 | 1.790 |
Why?
|
Biopsy | 11 | 2022 | 1187 | 1.770 |
Why?
|
Pharmacogenomic Testing | 16 | 2022 | 98 | 1.770 |
Why?
|
Female | 247 | 2024 | 45759 | 1.760 |
Why?
|
Precision Medicine | 19 | 2022 | 407 | 1.750 |
Why?
|
Fluorouracil | 29 | 2021 | 559 | 1.720 |
Why?
|
Adult | 190 | 2022 | 26348 | 1.720 |
Why?
|
Aged, 80 and over | 87 | 2021 | 6723 | 1.700 |
Why?
|
Neutropenia | 28 | 2019 | 216 | 1.650 |
Why?
|
Deoxycytidine | 11 | 2019 | 238 | 1.610 |
Why?
|
Antineoplastic Agents, Immunological | 5 | 2022 | 190 | 1.570 |
Why?
|
Administration, Oral | 32 | 2024 | 684 | 1.510 |
Why?
|
United States | 38 | 2024 | 6882 | 1.480 |
Why?
|
Paclitaxel | 22 | 2021 | 477 | 1.470 |
Why?
|
Biomedical Research | 5 | 2023 | 389 | 1.470 |
Why?
|
Antibodies, Monoclonal | 11 | 2021 | 1402 | 1.460 |
Why?
|
Cost-Benefit Analysis | 7 | 2024 | 454 | 1.460 |
Why?
|
Etoposide | 17 | 2009 | 198 | 1.400 |
Why?
|
Drug Industry | 6 | 2021 | 54 | 1.400 |
Why?
|
Genome, Human | 10 | 2019 | 767 | 1.380 |
Why?
|
Pharmacology, Clinical | 4 | 2020 | 8 | 1.360 |
Why?
|
ErbB Receptors | 8 | 2021 | 496 | 1.340 |
Why?
|
Treatment Outcome | 59 | 2023 | 8178 | 1.330 |
Why?
|
Breast Neoplasms | 25 | 2023 | 2980 | 1.290 |
Why?
|
Cytochrome P-450 CYP2D6 | 9 | 2022 | 52 | 1.280 |
Why?
|
Patient Selection | 11 | 2018 | 689 | 1.280 |
Why?
|
Microsomes, Liver | 17 | 2017 | 49 | 1.250 |
Why?
|
Thrombocytopenia | 18 | 2022 | 185 | 1.250 |
Why?
|
Endpoint Determination | 10 | 2016 | 60 | 1.250 |
Why?
|
Colorectal Neoplasms | 17 | 2024 | 970 | 1.240 |
Why?
|
Suramin | 11 | 2004 | 27 | 1.230 |
Why?
|
Quinazolines | 10 | 2010 | 221 | 1.230 |
Why?
|
Sulfonamides | 9 | 2017 | 318 | 1.210 |
Why?
|
Pyrimidines | 6 | 2021 | 372 | 1.200 |
Why?
|
Infusions, Intravenous | 38 | 2017 | 430 | 1.190 |
Why?
|
Melanoma | 6 | 2020 | 463 | 1.180 |
Why?
|
Protein-Tyrosine Kinases | 7 | 2012 | 307 | 1.180 |
Why?
|
Cisplatin | 20 | 2021 | 616 | 1.150 |
Why?
|
Phenylurea Compounds | 16 | 2018 | 114 | 1.110 |
Why?
|
Drug Dosage Calculations | 5 | 2020 | 16 | 1.110 |
Why?
|
Genome-Wide Association Study | 25 | 2024 | 1662 | 1.090 |
Why?
|
Angiogenesis Inhibitors | 10 | 2021 | 315 | 1.090 |
Why?
|
Food | 4 | 2018 | 86 | 1.090 |
Why?
|
Ketoconazole | 6 | 2017 | 26 | 1.070 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 283 | 1.060 |
Why?
|
Drug Costs | 3 | 2024 | 63 | 1.050 |
Why?
|
Drug Prescriptions | 8 | 2022 | 144 | 1.030 |
Why?
|
Pharmaceutical Preparations | 5 | 2024 | 91 | 1.010 |
Why?
|
Kidney Neoplasms | 13 | 2014 | 634 | 1.000 |
Why?
|
Glucuronides | 14 | 2017 | 34 | 0.990 |
Why?
|
Genetic Variation | 17 | 2020 | 1369 | 0.990 |
Why?
|
Tamoxifen | 6 | 2018 | 168 | 0.980 |
Why?
|
Niacinamide | 15 | 2014 | 115 | 0.980 |
Why?
|
Models, Biological | 26 | 2019 | 1764 | 0.970 |
Why?
|
Area Under Curve | 28 | 2019 | 333 | 0.970 |
Why?
|
Genetic Therapy | 2 | 2023 | 369 | 0.960 |
Why?
|
HIV Protease Inhibitors | 2 | 2022 | 21 | 0.960 |
Why?
|
Isoenzymes | 9 | 2015 | 273 | 0.960 |
Why?
|
Anemia | 6 | 2022 | 126 | 0.950 |
Why?
|
Imides | 9 | 2001 | 26 | 0.950 |
Why?
|
Phosphotransferases | 2 | 2017 | 65 | 0.950 |
Why?
|
Prospective Studies | 27 | 2022 | 4271 | 0.940 |
Why?
|
Orphan Drug Production | 1 | 2023 | 4 | 0.930 |
Why?
|
Isoquinolines | 9 | 2001 | 73 | 0.920 |
Why?
|
Carcinoma, Renal Cell | 11 | 2014 | 434 | 0.920 |
Why?
|
Carbolines | 3 | 2022 | 8 | 0.910 |
Why?
|
Decision Support Systems, Clinical | 5 | 2019 | 105 | 0.910 |
Why?
|
Heterocyclic Compounds, 4 or More Rings | 3 | 2022 | 16 | 0.900 |
Why?
|
Leukemia, Hairy Cell | 26 | 1994 | 186 | 0.900 |
Why?
|
Conflict of Interest | 5 | 2015 | 67 | 0.900 |
Why?
|
Indoles | 6 | 2017 | 310 | 0.900 |
Why?
|
Clinical Trials, Phase III as Topic | 8 | 2015 | 173 | 0.890 |
Why?
|
Body Surface Area | 6 | 2022 | 36 | 0.890 |
Why?
|
Liver | 18 | 2020 | 1244 | 0.890 |
Why?
|
Ethics Committees, Research | 2 | 2022 | 33 | 0.870 |
Why?
|
Leukemia | 9 | 2021 | 321 | 0.850 |
Why?
|
Prodrugs | 5 | 2008 | 49 | 0.850 |
Why?
|
Quinoxalines | 4 | 2014 | 50 | 0.840 |
Why?
|
Piperazines | 3 | 2022 | 280 | 0.840 |
Why?
|
Ritonavir | 1 | 2022 | 12 | 0.830 |
Why?
|
Bevacizumab | 13 | 2024 | 287 | 0.820 |
Why?
|
Arylamine N-Acetyltransferase | 2 | 2021 | 12 | 0.820 |
Why?
|
Physicians | 3 | 2021 | 684 | 0.810 |
Why?
|
Leucovorin | 18 | 2021 | 222 | 0.810 |
Why?
|
Fear | 1 | 2022 | 80 | 0.800 |
Why?
|
Diarrhea | 10 | 2009 | 182 | 0.800 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2012 | 116 | 0.800 |
Why?
|
Computer Simulation | 6 | 2023 | 1095 | 0.800 |
Why?
|
Liver Diseases | 4 | 2007 | 250 | 0.800 |
Why?
|
Prostatic Neoplasms | 13 | 2024 | 1764 | 0.800 |
Why?
|
Patents as Topic | 1 | 2021 | 12 | 0.790 |
Why?
|
Janus Kinase 2 | 1 | 2021 | 60 | 0.790 |
Why?
|
Patient Harm | 1 | 2021 | 7 | 0.790 |
Why?
|
Peripheral Nervous System Diseases | 6 | 2020 | 87 | 0.790 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 143 | 0.780 |
Why?
|
Antifungal Agents | 3 | 2007 | 119 | 0.780 |
Why?
|
Industry | 3 | 2023 | 17 | 0.780 |
Why?
|
Health Care Costs | 3 | 2021 | 235 | 0.770 |
Why?
|
Biological Products | 2 | 2020 | 147 | 0.770 |
Why?
|
Topotecan | 9 | 2005 | 45 | 0.760 |
Why?
|
Cardiotoxicity | 1 | 2021 | 10 | 0.760 |
Why?
|
Metabolic Clearance Rate | 17 | 2017 | 120 | 0.750 |
Why?
|
Methyltransferases | 5 | 2013 | 192 | 0.750 |
Why?
|
Informed Consent | 11 | 2022 | 273 | 0.740 |
Why?
|
Taxoids | 6 | 2016 | 130 | 0.730 |
Why?
|
Multidrug Resistance-Associated Proteins | 5 | 2013 | 27 | 0.720 |
Why?
|
Pharmacogenomic Variants | 4 | 2021 | 42 | 0.710 |
Why?
|
Creatinine | 6 | 2015 | 295 | 0.700 |
Why?
|
Cytochrome P-450 CYP3A | 10 | 2017 | 42 | 0.690 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2019 | 13 | 0.670 |
Why?
|
Research | 4 | 2019 | 251 | 0.670 |
Why?
|
Triazoles | 4 | 2012 | 100 | 0.660 |
Why?
|
Interleukin-6 | 1 | 2020 | 260 | 0.660 |
Why?
|
Topoisomerase II Inhibitors | 4 | 2009 | 27 | 0.660 |
Why?
|
Kidney Diseases | 4 | 2007 | 319 | 0.660 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2020 | 169 | 0.650 |
Why?
|
Doxorubicin | 9 | 2007 | 298 | 0.650 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2018 | 185 | 0.650 |
Why?
|
Interferon-alpha | 16 | 2004 | 236 | 0.640 |
Why?
|
Caffeine | 1 | 2019 | 83 | 0.630 |
Why?
|
Point-of-Care Systems | 3 | 2019 | 144 | 0.620 |
Why?
|
Physician's Role | 2 | 2017 | 176 | 0.620 |
Why?
|
National Cancer Institute (U.S.) | 7 | 2023 | 73 | 0.620 |
Why?
|
Megestrol Acetate | 1 | 2017 | 10 | 0.610 |
Why?
|
Metabolome | 2 | 2017 | 49 | 0.610 |
Why?
|
Patient Education as Topic | 2 | 2019 | 356 | 0.610 |
Why?
|
Pyrazoles | 5 | 2022 | 150 | 0.600 |
Why?
|
Protein Kinases | 3 | 2009 | 212 | 0.600 |
Why?
|
Hydroxamic Acids | 3 | 2014 | 51 | 0.600 |
Why?
|
Practice Patterns, Physicians' | 7 | 2021 | 597 | 0.590 |
Why?
|
Parkinson Disease | 1 | 2019 | 143 | 0.590 |
Why?
|
Medical Order Entry Systems | 1 | 2017 | 25 | 0.590 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 10 | 2006 | 29 | 0.580 |
Why?
|
Nontherapeutic Human Experimentation | 7 | 2017 | 20 | 0.580 |
Why?
|
Immunotherapy | 2 | 2020 | 661 | 0.570 |
Why?
|
Neovascularization, Pathologic | 5 | 2018 | 364 | 0.570 |
Why?
|
Carboplatin | 5 | 2021 | 304 | 0.570 |
Why?
|
Practice Guidelines as Topic | 8 | 2024 | 1039 | 0.570 |
Why?
|
Perioperative Care | 5 | 2022 | 167 | 0.560 |
Why?
|
Guanine | 4 | 2002 | 208 | 0.550 |
Why?
|
Recombinant Proteins | 30 | 2017 | 1020 | 0.550 |
Why?
|
Kidney | 6 | 2015 | 1145 | 0.540 |
Why?
|
Leukopenia | 12 | 2002 | 66 | 0.530 |
Why?
|
Germ-Line Mutation | 7 | 2020 | 341 | 0.530 |
Why?
|
Capecitabine | 6 | 2020 | 98 | 0.520 |
Why?
|
Guidelines as Topic | 2 | 2019 | 159 | 0.520 |
Why?
|
Pancreatic Neoplasms | 4 | 2019 | 659 | 0.520 |
Why?
|
Topoisomerase I Inhibitors | 7 | 2020 | 34 | 0.520 |
Why?
|
Attitude of Health Personnel | 4 | 2019 | 642 | 0.520 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2020 | 612 | 0.520 |
Why?
|
RNA, Messenger | 14 | 2018 | 2009 | 0.510 |
Why?
|
Oxidoreductases | 10 | 2002 | 112 | 0.510 |
Why?
|
Introns | 4 | 2013 | 298 | 0.510 |
Why?
|
Uracil | 7 | 2002 | 56 | 0.510 |
Why?
|
Depsipeptides | 1 | 2015 | 30 | 0.510 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 3 | 2013 | 44 | 0.510 |
Why?
|
Genetic Predisposition to Disease | 15 | 2019 | 2322 | 0.510 |
Why?
|
Meaningful Use | 1 | 2014 | 2 | 0.500 |
Why?
|
Morpholines | 1 | 2015 | 69 | 0.500 |
Why?
|
Prostate-Specific Antigen | 5 | 2018 | 358 | 0.500 |
Why?
|
Oligonucleotides, Antisense | 2 | 2005 | 68 | 0.500 |
Why?
|
Carbazoles | 2 | 2005 | 33 | 0.500 |
Why?
|
Head and Neck Neoplasms | 10 | 2008 | 1057 | 0.490 |
Why?
|
Professional Practice | 1 | 2015 | 46 | 0.490 |
Why?
|
Renal Insufficiency | 2 | 2009 | 102 | 0.490 |
Why?
|
Lymphoma | 7 | 2021 | 264 | 0.480 |
Why?
|
Time Factors | 22 | 2020 | 5319 | 0.480 |
Why?
|
Hypertension, Pulmonary | 3 | 2022 | 352 | 0.470 |
Why?
|
Cohort Studies | 18 | 2019 | 2837 | 0.470 |
Why?
|
Bilirubin | 13 | 2010 | 130 | 0.470 |
Why?
|
Reproducibility of Results | 11 | 2021 | 2746 | 0.470 |
Why?
|
Regression Analysis | 14 | 2010 | 594 | 0.470 |
Why?
|
Adenocarcinoma | 5 | 2018 | 1184 | 0.470 |
Why?
|
Sample Size | 3 | 2011 | 129 | 0.460 |
Why?
|
Hypertension | 3 | 2021 | 733 | 0.460 |
Why?
|
Interferon Type I | 17 | 1990 | 178 | 0.460 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 67 | 0.450 |
Why?
|
Linkage Disequilibrium | 7 | 2013 | 474 | 0.450 |
Why?
|
Young Adult | 22 | 2020 | 6218 | 0.450 |
Why?
|
Estrogen Antagonists | 1 | 2013 | 48 | 0.450 |
Why?
|
Program Development | 1 | 2014 | 123 | 0.450 |
Why?
|
Biological Availability | 7 | 2017 | 93 | 0.450 |
Why?
|
Risk Assessment | 19 | 2021 | 2286 | 0.450 |
Why?
|
Dietary Fats | 1 | 2014 | 136 | 0.450 |
Why?
|
Drug Delivery Systems | 2 | 2012 | 179 | 0.450 |
Why?
|
Hearing Loss | 1 | 2013 | 59 | 0.440 |
Why?
|
Catechol O-Methyltransferase | 1 | 2013 | 69 | 0.440 |
Why?
|
Ambulatory Care | 2 | 2014 | 186 | 0.440 |
Why?
|
Proto-Oncogene Proteins c-raf | 2 | 2004 | 48 | 0.440 |
Why?
|
Models, Statistical | 8 | 2020 | 575 | 0.440 |
Why?
|
Food Labeling | 1 | 2012 | 8 | 0.440 |
Why?
|
Drug Therapy | 5 | 2016 | 70 | 0.440 |
Why?
|
Indazoles | 5 | 2017 | 67 | 0.430 |
Why?
|
Cladribine | 5 | 2004 | 35 | 0.430 |
Why?
|
Phenotype | 19 | 2020 | 2435 | 0.430 |
Why?
|
Enzymes | 2 | 2006 | 47 | 0.430 |
Why?
|
Universities | 1 | 2013 | 146 | 0.420 |
Why?
|
Private Sector | 2 | 2011 | 19 | 0.420 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2018 | 421 | 0.420 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 223 | 0.420 |
Why?
|
Glucuronates | 8 | 2007 | 22 | 0.410 |
Why?
|
Snake Venoms | 2 | 2015 | 10 | 0.410 |
Why?
|
Medicine | 3 | 2007 | 90 | 0.410 |
Why?
|
Clinical Protocols | 2 | 2014 | 157 | 0.400 |
Why?
|
Investments | 1 | 2011 | 6 | 0.400 |
Why?
|
Pyrazolones | 2 | 2002 | 4 | 0.400 |
Why?
|
Warfarin | 3 | 2019 | 104 | 0.400 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2018 | 156 | 0.400 |
Why?
|
Patient Safety | 2 | 2020 | 215 | 0.400 |
Why?
|
Haplotypes | 7 | 2012 | 637 | 0.390 |
Why?
|
Commerce | 1 | 2011 | 30 | 0.390 |
Why?
|
Mass Media | 1 | 2011 | 26 | 0.390 |
Why?
|
Vinblastine | 7 | 1998 | 108 | 0.390 |
Why?
|
Technology, Pharmaceutical | 2 | 2009 | 32 | 0.390 |
Why?
|
Neoplasm Staging | 14 | 2021 | 1983 | 0.390 |
Why?
|
Academic Medical Centers | 1 | 2014 | 383 | 0.390 |
Why?
|
Germ Cells | 1 | 2012 | 130 | 0.380 |
Why?
|
Cost Sharing | 1 | 2011 | 16 | 0.380 |
Why?
|
Kinetics | 10 | 2017 | 1530 | 0.380 |
Why?
|
Interleukin-17 | 1 | 2011 | 105 | 0.380 |
Why?
|
Body Weight | 4 | 2020 | 455 | 0.370 |
Why?
|
Gene Expression Regulation | 5 | 2020 | 1977 | 0.370 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2011 | 60 | 0.370 |
Why?
|
Eating | 2 | 2012 | 165 | 0.370 |
Why?
|
Clinical Decision-Making | 5 | 2021 | 275 | 0.370 |
Why?
|
Mutation | 8 | 2021 | 4097 | 0.370 |
Why?
|
Cyclosporine | 5 | 2007 | 239 | 0.370 |
Why?
|
Health Resources | 1 | 2011 | 82 | 0.370 |
Why?
|
Research Subjects | 9 | 2007 | 73 | 0.370 |
Why?
|
Alleles | 6 | 2017 | 1132 | 0.370 |
Why?
|
Patient Portals | 2 | 2020 | 17 | 0.350 |
Why?
|
Follow-Up Studies | 15 | 2021 | 3655 | 0.350 |
Why?
|
Aminopyridines | 2 | 2022 | 40 | 0.350 |
Why?
|
Ovarian Neoplasms | 3 | 2008 | 759 | 0.350 |
Why?
|
Cost Savings | 2 | 2020 | 69 | 0.350 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 29 | 0.350 |
Why?
|
Drug Evaluation | 17 | 2002 | 138 | 0.340 |
Why?
|
Population Groups | 1 | 2009 | 42 | 0.340 |
Why?
|
Dinucleotide Repeats | 1 | 2009 | 14 | 0.340 |
Why?
|
Drug Design | 8 | 2011 | 124 | 0.340 |
Why?
|
Hepatic Insufficiency | 1 | 2009 | 1 | 0.340 |
Why?
|
Promoter Regions, Genetic | 7 | 2012 | 956 | 0.340 |
Why?
|
Acetylation | 6 | 2021 | 132 | 0.340 |
Why?
|
Decision Support Techniques | 2 | 2021 | 165 | 0.330 |
Why?
|
Substrate Specificity | 5 | 2017 | 352 | 0.330 |
Why?
|
Fatigue | 8 | 2022 | 178 | 0.330 |
Why?
|
Genetics, Population | 2 | 2009 | 404 | 0.330 |
Why?
|
Cell Line, Tumor | 9 | 2018 | 2538 | 0.320 |
Why?
|
Double-Blind Method | 9 | 2019 | 1716 | 0.320 |
Why?
|
Prescription Drugs | 2 | 2019 | 36 | 0.320 |
Why?
|
Drug Discovery | 1 | 2009 | 107 | 0.320 |
Why?
|
Phosphorylcholine | 1 | 2008 | 28 | 0.320 |
Why?
|
Organizations, Nonprofit | 1 | 2008 | 8 | 0.320 |
Why?
|
Anesthesiology | 2 | 2022 | 160 | 0.320 |
Why?
|
Biomedical Technology | 1 | 2008 | 21 | 0.320 |
Why?
|
Immunosuppressive Agents | 4 | 2007 | 994 | 0.320 |
Why?
|
Biomarkers | 2 | 2014 | 1759 | 0.310 |
Why?
|
Organoplatinum Compounds | 4 | 2020 | 96 | 0.310 |
Why?
|
Disease Progression | 6 | 2012 | 1490 | 0.310 |
Why?
|
Cytochrome P-450 Enzyme System | 7 | 2008 | 79 | 0.310 |
Why?
|
Quantitative Trait Loci | 6 | 2024 | 606 | 0.310 |
Why?
|
Data Interpretation, Statistical | 5 | 2016 | 299 | 0.310 |
Why?
|
Myelodysplastic Syndromes | 3 | 2014 | 351 | 0.300 |
Why?
|
Drug Packaging | 3 | 2020 | 7 | 0.300 |
Why?
|
Government Regulation | 2 | 2007 | 49 | 0.300 |
Why?
|
Salvage Therapy | 4 | 2008 | 235 | 0.300 |
Why?
|
Evidence-Based Medicine | 5 | 2021 | 431 | 0.300 |
Why?
|
Genetic Privacy | 1 | 2007 | 12 | 0.300 |
Why?
|
Tubulin Modulators | 2 | 2020 | 24 | 0.300 |
Why?
|
Liposomes | 2 | 2004 | 93 | 0.290 |
Why?
|
Decision Making | 5 | 2018 | 661 | 0.290 |
Why?
|
Glomerular Filtration Rate | 2 | 2011 | 279 | 0.290 |
Why?
|
DNA-Binding Proteins | 4 | 2012 | 1240 | 0.290 |
Why?
|
Models, Genetic | 1 | 2012 | 942 | 0.290 |
Why?
|
Phenobarbital | 4 | 2006 | 33 | 0.290 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2020 | 525 | 0.290 |
Why?
|
Prejudice | 1 | 2007 | 48 | 0.290 |
Why?
|
Medical Records | 2 | 2007 | 121 | 0.280 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2014 | 92 | 0.280 |
Why?
|
Intestinal Absorption | 3 | 2017 | 124 | 0.280 |
Why?
|
Delivery of Health Care | 3 | 2023 | 433 | 0.280 |
Why?
|
Naphthalimides | 9 | 2001 | 17 | 0.280 |
Why?
|
Technology Transfer | 1 | 2006 | 3 | 0.280 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 253 | 0.270 |
Why?
|
Radiosurgery | 2 | 2021 | 280 | 0.270 |
Why?
|
Disease-Free Survival | 8 | 2016 | 1213 | 0.270 |
Why?
|
Drug Therapy, Combination | 6 | 2019 | 799 | 0.270 |
Why?
|
Cytochrome P-450 CYP3A Inhibitors | 2 | 2017 | 5 | 0.270 |
Why?
|
Erlotinib Hydrochloride | 5 | 2010 | 90 | 0.270 |
Why?
|
Organophosphonates | 9 | 2001 | 50 | 0.270 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 84 | 0.270 |
Why?
|
Abiraterone Acetate | 2 | 2018 | 12 | 0.260 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2005 | 41 | 0.260 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2013 | 406 | 0.260 |
Why?
|
Prognosis | 14 | 2021 | 3750 | 0.260 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 3 | 2002 | 118 | 0.260 |
Why?
|
Pharmacy and Therapeutics Committee | 3 | 2010 | 5 | 0.260 |
Why?
|
Cytochrome P-450 CYP2C9 | 2 | 2019 | 20 | 0.260 |
Why?
|
Receptor, trkA | 1 | 2005 | 15 | 0.250 |
Why?
|
Survival Analysis | 12 | 2018 | 1542 | 0.250 |
Why?
|
Liver Neoplasms | 3 | 2013 | 771 | 0.250 |
Why?
|
Neuroendocrine Tumors | 1 | 2006 | 109 | 0.250 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2010 | 162 | 0.250 |
Why?
|
Anthraquinones | 2 | 2002 | 8 | 0.250 |
Why?
|
Dipeptides | 1 | 2004 | 42 | 0.240 |
Why?
|
Chicago | 4 | 2014 | 1411 | 0.240 |
Why?
|
Maytansine | 1 | 2004 | 10 | 0.240 |
Why?
|
Thionucleotides | 2 | 2002 | 56 | 0.240 |
Why?
|
Genomics | 3 | 2019 | 747 | 0.240 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2024 | 17 | 0.240 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2004 | 112 | 0.240 |
Why?
|
Clinical Medicine | 3 | 2015 | 34 | 0.240 |
Why?
|
Fasting | 2 | 2018 | 163 | 0.240 |
Why?
|
Patient Compliance | 2 | 2005 | 228 | 0.240 |
Why?
|
Information Dissemination | 3 | 2019 | 111 | 0.240 |
Why?
|
Gene Expression Regulation, Enzymologic | 4 | 2010 | 217 | 0.240 |
Why?
|
Risk Factors | 12 | 2024 | 5449 | 0.240 |
Why?
|
Granulocyte Colony-Stimulating Factor | 7 | 2003 | 166 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2018 | 1352 | 0.230 |
Why?
|
Acetyltransferases | 2 | 2021 | 32 | 0.230 |
Why?
|
Glutathione Transferase | 6 | 2005 | 112 | 0.230 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2023 | 38 | 0.230 |
Why?
|
Greenhouse Gases | 1 | 2023 | 1 | 0.230 |
Why?
|
Animals | 25 | 2016 | 27233 | 0.230 |
Why?
|
Genetic Markers | 3 | 2018 | 478 | 0.230 |
Why?
|
Interleukin-2 | 7 | 2004 | 251 | 0.230 |
Why?
|
Pyrazines | 4 | 2000 | 94 | 0.220 |
Why?
|
Government | 1 | 2023 | 9 | 0.220 |
Why?
|
Physician-Patient Relations | 4 | 2019 | 622 | 0.220 |
Why?
|
Neoplasm Metastasis | 11 | 2024 | 1096 | 0.220 |
Why?
|
Sensory Receptor Cells | 2 | 2014 | 36 | 0.220 |
Why?
|
Fever | 3 | 2020 | 127 | 0.220 |
Why?
|
Neoplasms, Squamous Cell | 2 | 2008 | 20 | 0.220 |
Why?
|
Prednisone | 4 | 2018 | 258 | 0.220 |
Why?
|
RNA, Long Noncoding | 1 | 2024 | 116 | 0.210 |
Why?
|
Dioxolanes | 1 | 2002 | 8 | 0.210 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2010 | 262 | 0.210 |
Why?
|
Survival Rate | 10 | 2021 | 1883 | 0.210 |
Why?
|
DNA Damage | 2 | 2017 | 371 | 0.210 |
Why?
|
Apoptosis | 2 | 2008 | 1718 | 0.210 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2004 | 60 | 0.210 |
Why?
|
Metabolic Networks and Pathways | 3 | 2013 | 80 | 0.210 |
Why?
|
Lactams | 1 | 2022 | 11 | 0.210 |
Why?
|
ATP-Binding Cassette Transporters | 2 | 2016 | 142 | 0.210 |
Why?
|
DNA, Antisense | 1 | 2002 | 15 | 0.210 |
Why?
|
Lactams, Macrocyclic | 1 | 2022 | 14 | 0.210 |
Why?
|
Alanine | 2 | 2019 | 85 | 0.210 |
Why?
|
Transcription, Genetic | 3 | 2017 | 1156 | 0.210 |
Why?
|
Triazines | 2 | 2019 | 53 | 0.210 |
Why?
|
Tramadol | 1 | 2022 | 14 | 0.200 |
Why?
|
Anilides | 2 | 2013 | 48 | 0.200 |
Why?
|
Reimbursement, Incentive | 1 | 2022 | 37 | 0.200 |
Why?
|
Health Services Accessibility | 2 | 2024 | 418 | 0.200 |
Why?
|
Leukemia, Myeloid | 2 | 2014 | 249 | 0.200 |
Why?
|
Kv1.3 Potassium Channel | 1 | 2021 | 14 | 0.200 |
Why?
|
Pain Management | 2 | 2021 | 134 | 0.200 |
Why?
|
Celecoxib | 2 | 2019 | 31 | 0.200 |
Why?
|
Uridine Diphosphate | 2 | 1998 | 5 | 0.200 |
Why?
|
Genetic Testing | 4 | 2019 | 538 | 0.200 |
Why?
|
Stomatitis | 5 | 2004 | 30 | 0.200 |
Why?
|
Biotransformation | 6 | 2009 | 50 | 0.200 |
Why?
|
Cytosine | 1 | 2002 | 128 | 0.200 |
Why?
|
Proteinuria | 1 | 2021 | 67 | 0.200 |
Why?
|
Mercaptopurine | 3 | 2009 | 53 | 0.200 |
Why?
|
Oxidation-Reduction | 3 | 2017 | 385 | 0.200 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 16 | 0.200 |
Why?
|
Aminoquinolines | 1 | 2001 | 17 | 0.200 |
Why?
|
Indenes | 1 | 2001 | 10 | 0.190 |
Why?
|
Intercalating Agents | 2 | 1993 | 12 | 0.190 |
Why?
|
Epothilones | 2 | 2019 | 13 | 0.190 |
Why?
|
Acrylamides | 1 | 2021 | 32 | 0.190 |
Why?
|
Human Genome Project | 1 | 2001 | 19 | 0.190 |
Why?
|
Hockey | 1 | 2021 | 9 | 0.190 |
Why?
|
Nitriles | 2 | 2012 | 160 | 0.190 |
Why?
|
Protein Kinase C | 1 | 2002 | 268 | 0.190 |
Why?
|
Research Personnel | 2 | 2001 | 70 | 0.190 |
Why?
|
Anesthetics | 1 | 2021 | 53 | 0.190 |
Why?
|
Patient Participation | 4 | 2015 | 224 | 0.190 |
Why?
|
Government Agencies | 1 | 2020 | 11 | 0.190 |
Why?
|
Hematologic Neoplasms | 3 | 2014 | 336 | 0.190 |
Why?
|
Patient-Centered Care | 1 | 2023 | 207 | 0.190 |
Why?
|
Collagen | 1 | 2002 | 296 | 0.190 |
Why?
|
Anticarcinogenic Agents | 3 | 2013 | 73 | 0.190 |
Why?
|
Antidotes | 2 | 1997 | 23 | 0.190 |
Why?
|
Bile | 2 | 2002 | 57 | 0.190 |
Why?
|
Organizational Policy | 1 | 2001 | 55 | 0.190 |
Why?
|
Rheumatology | 1 | 2021 | 35 | 0.180 |
Why?
|
Sarcoma | 4 | 2009 | 220 | 0.180 |
Why?
|
Albumins | 2 | 2019 | 130 | 0.180 |
Why?
|
Safety | 4 | 2010 | 151 | 0.180 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 436 | 0.180 |
Why?
|
Signal Transduction | 6 | 2013 | 3368 | 0.180 |
Why?
|
Genotyping Techniques | 3 | 2018 | 69 | 0.180 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 173 | 0.180 |
Why?
|
Thymidylate Synthase | 4 | 2003 | 13 | 0.180 |
Why?
|
Nausea | 5 | 2022 | 176 | 0.180 |
Why?
|
Peptide Fragments | 1 | 2002 | 460 | 0.180 |
Why?
|
Societies, Medical | 2 | 2019 | 563 | 0.180 |
Why?
|
Analgesics | 1 | 2021 | 119 | 0.180 |
Why?
|
Splenectomy | 9 | 1992 | 82 | 0.180 |
Why?
|
Testicular Neoplasms | 2 | 2019 | 113 | 0.180 |
Why?
|
Remission Induction | 17 | 2008 | 735 | 0.180 |
Why?
|
Models, Theoretical | 6 | 2014 | 490 | 0.180 |
Why?
|
Equivalence Trials as Topic | 1 | 2019 | 5 | 0.180 |
Why?
|
Algorithms | 3 | 2019 | 1868 | 0.180 |
Why?
|
Anesthesia | 1 | 2022 | 169 | 0.180 |
Why?
|
Europe | 1 | 2020 | 314 | 0.180 |
Why?
|
DNA, Neoplasm | 3 | 2018 | 269 | 0.180 |
Why?
|
Schools, Medical | 1 | 2001 | 134 | 0.170 |
Why?
|
Bone Marrow | 12 | 2001 | 445 | 0.170 |
Why?
|
Drug Utilization | 1 | 2020 | 65 | 0.170 |
Why?
|
C-Reactive Protein | 1 | 2020 | 195 | 0.170 |
Why?
|
Leukocytes, Mononuclear | 4 | 2018 | 205 | 0.170 |
Why?
|
Circadian Rhythm | 2 | 2015 | 303 | 0.170 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2017 | 124 | 0.170 |
Why?
|
Neoplasms, Second Primary | 2 | 1992 | 258 | 0.170 |
Why?
|
Blood Pressure | 3 | 2014 | 893 | 0.170 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 2 | 2018 | 57 | 0.170 |
Why?
|
Inpatients | 1 | 2022 | 308 | 0.170 |
Why?
|
Leukocyte Count | 10 | 1996 | 222 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2011 | 479 | 0.170 |
Why?
|
Cytidine Deaminase | 1 | 2019 | 43 | 0.170 |
Why?
|
Hepatocytes | 4 | 2013 | 128 | 0.170 |
Why?
|
Ethics, Medical | 4 | 2008 | 308 | 0.170 |
Why?
|
Tegafur | 2 | 1999 | 17 | 0.160 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 269 | 0.160 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 146 | 0.160 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2008 | 782 | 0.160 |
Why?
|
Lymphoproliferative Disorders | 3 | 1996 | 111 | 0.160 |
Why?
|
Withholding Treatment | 1 | 2019 | 113 | 0.160 |
Why?
|
Benzamides | 2 | 2013 | 239 | 0.160 |
Why?
|
Equilibrative Nucleoside Transporter 1 | 1 | 2018 | 2 | 0.160 |
Why?
|
Exanthema | 2 | 2009 | 38 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2005 | 393 | 0.160 |
Why?
|
Receptors, IgG | 1 | 2018 | 52 | 0.160 |
Why?
|
Medication Adherence | 1 | 2020 | 134 | 0.160 |
Why?
|
Bayes Theorem | 1 | 2020 | 368 | 0.160 |
Why?
|
Singapore | 1 | 2018 | 16 | 0.160 |
Why?
|
Cetuximab | 4 | 2021 | 113 | 0.160 |
Why?
|
Receptors, Estrogen | 3 | 2016 | 386 | 0.160 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2016 | 267 | 0.160 |
Why?
|
Dehydroepiandrosterone | 1 | 2018 | 51 | 0.160 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 46 | 0.150 |
Why?
|
Troleandomycin | 1 | 2017 | 3 | 0.150 |
Why?
|
Bone Marrow Diseases | 3 | 1993 | 40 | 0.150 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 127 | 0.150 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 1 | 2017 | 12 | 0.150 |
Why?
|
Career Choice | 1 | 2019 | 145 | 0.150 |
Why?
|
Liver Function Tests | 4 | 2007 | 93 | 0.150 |
Why?
|
Erythropoietin | 3 | 2013 | 89 | 0.150 |
Why?
|
Statistics as Topic | 3 | 1993 | 235 | 0.150 |
Why?
|
History, 20th Century | 2 | 2011 | 307 | 0.150 |
Why?
|
Receptors, Calcitriol | 1 | 2018 | 129 | 0.150 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 72 | 0.150 |
Why?
|
Surveys and Questionnaires | 9 | 2020 | 2593 | 0.150 |
Why?
|
Diphtheria Toxin | 4 | 1998 | 20 | 0.150 |
Why?
|
Terminology as Topic | 1 | 2019 | 219 | 0.150 |
Why?
|
Combined Modality Therapy | 11 | 2021 | 1709 | 0.150 |
Why?
|
Adrenal Cortex Diseases | 1 | 1996 | 6 | 0.140 |
Why?
|
Addison Disease | 1 | 1996 | 4 | 0.140 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2018 | 46 | 0.140 |
Why?
|
Specialization | 2 | 2007 | 65 | 0.140 |
Why?
|
Motor Neuron Disease | 1 | 1997 | 21 | 0.140 |
Why?
|
Valproic Acid | 1 | 1997 | 24 | 0.140 |
Why?
|
Therapeutic Human Experimentation | 2 | 1993 | 20 | 0.140 |
Why?
|
Cardiovascular Agents | 2 | 2015 | 54 | 0.140 |
Why?
|
Neural Conduction | 1 | 1997 | 71 | 0.140 |
Why?
|
Cytochrome P-450 CYP2C19 | 2 | 2014 | 8 | 0.140 |
Why?
|
Demyelinating Diseases | 1 | 1997 | 67 | 0.140 |
Why?
|
Glioma | 1 | 1999 | 291 | 0.140 |
Why?
|
Intersectoral Collaboration | 1 | 2016 | 10 | 0.140 |
Why?
|
Periodicals as Topic | 1 | 2019 | 168 | 0.140 |
Why?
|
Metformin | 1 | 2018 | 123 | 0.140 |
Why?
|
Biliary Tract | 1 | 1996 | 13 | 0.140 |
Why?
|
Healthy Volunteers | 1 | 2017 | 145 | 0.140 |
Why?
|
Testosterone | 1 | 2018 | 275 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2010 | 1256 | 0.140 |
Why?
|
Neoplasm Proteins | 5 | 2016 | 539 | 0.140 |
Why?
|
Critical Care | 1 | 2019 | 378 | 0.140 |
Why?
|
Cyclophosphamide | 7 | 2002 | 300 | 0.130 |
Why?
|
Atazanavir Sulfate | 1 | 2015 | 1 | 0.130 |
Why?
|
Hyperbilirubinemia | 1 | 2015 | 21 | 0.130 |
Why?
|
Floxuridine | 2 | 1993 | 12 | 0.130 |
Why?
|
Jaundice | 1 | 2015 | 14 | 0.130 |
Why?
|
Polyneuropathies | 1 | 2016 | 27 | 0.130 |
Why?
|
Hydroxyurea | 6 | 1998 | 239 | 0.130 |
Why?
|
Chromatography, High Pressure Liquid | 5 | 2004 | 315 | 0.130 |
Why?
|
Drug Eruptions | 2 | 2006 | 34 | 0.130 |
Why?
|
Flavonoids | 4 | 2007 | 87 | 0.130 |
Why?
|
Glucocorticoids | 1 | 2018 | 358 | 0.130 |
Why?
|
Attitude to Health | 4 | 2017 | 221 | 0.130 |
Why?
|
Random Allocation | 6 | 2008 | 329 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 318 | 0.130 |
Why?
|
Placebos | 3 | 2017 | 214 | 0.130 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 450 | 0.130 |
Why?
|
Selection Bias | 2 | 2011 | 37 | 0.130 |
Why?
|
Advisory Committees | 1 | 2015 | 88 | 0.130 |
Why?
|
Sulfonic Acids | 1 | 1995 | 9 | 0.130 |
Why?
|
Collagen Type I | 1 | 2015 | 72 | 0.130 |
Why?
|
Naphthyridines | 1 | 2015 | 27 | 0.130 |
Why?
|
Treatment Failure | 2 | 2011 | 289 | 0.120 |
Why?
|
Nitrosamines | 1 | 2014 | 8 | 0.120 |
Why?
|
Hydrocortisone | 1 | 1996 | 303 | 0.120 |
Why?
|
Gene Expression Profiling | 6 | 2013 | 1427 | 0.120 |
Why?
|
Nedocromil | 1 | 2014 | 6 | 0.120 |
Why?
|
Inactivation, Metabolic | 2 | 2006 | 8 | 0.120 |
Why?
|
Loss of Heterozygosity | 1 | 2014 | 86 | 0.120 |
Why?
|
Sex Characteristics | 1 | 1997 | 321 | 0.120 |
Why?
|
DNA Primers | 2 | 2006 | 543 | 0.120 |
Why?
|
Drug Resistance | 3 | 1993 | 232 | 0.120 |
Why?
|
Comprehension | 5 | 2000 | 80 | 0.120 |
Why?
|
Lymphopenia | 2 | 2012 | 31 | 0.120 |
Why?
|
Busulfan | 1 | 2014 | 41 | 0.120 |
Why?
|
Adolescent | 11 | 2020 | 9157 | 0.120 |
Why?
|
Fees and Charges | 1 | 2014 | 14 | 0.120 |
Why?
|
Drug Synergism | 5 | 2018 | 305 | 0.120 |
Why?
|
Epirubicin | 3 | 2021 | 14 | 0.120 |
Why?
|
Phthalazines | 1 | 2014 | 43 | 0.120 |
Why?
|
Aldehyde Oxidase | 1 | 2014 | 3 | 0.120 |
Why?
|
Forced Expiratory Volume | 1 | 2014 | 124 | 0.120 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2015 | 75 | 0.120 |
Why?
|
Azacitidine | 1 | 2014 | 139 | 0.120 |
Why?
|
Pyrroles | 2 | 2015 | 186 | 0.120 |
Why?
|
Cytochrome P-450 CYP2C8 | 1 | 2013 | 3 | 0.120 |
Why?
|
Receptors, Interleukin-2 | 5 | 1998 | 67 | 0.120 |
Why?
|
Thromboembolism | 1 | 2014 | 119 | 0.120 |
Why?
|
Disclosure | 5 | 2000 | 109 | 0.120 |
Why?
|
Sex Factors | 5 | 2020 | 1063 | 0.120 |
Why?
|
Organic Cation Transporter 1 | 1 | 2013 | 1 | 0.120 |
Why?
|
Anti-Asthmatic Agents | 1 | 2014 | 75 | 0.120 |
Why?
|
Child | 9 | 2020 | 7089 | 0.110 |
Why?
|
Hepatocyte Nuclear Factor 1 | 1 | 2013 | 30 | 0.110 |
Why?
|
Portraits as Topic | 1 | 2013 | 6 | 0.110 |
Why?
|
Patient Outcome Assessment | 1 | 2014 | 84 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 2 | 1999 | 1094 | 0.110 |
Why?
|
Carcinoma, Small Cell | 3 | 1997 | 133 | 0.110 |
Why?
|
Arteries | 1 | 2014 | 181 | 0.110 |
Why?
|
Medicare | 1 | 2017 | 420 | 0.110 |
Why?
|
Brain Diseases | 1 | 1995 | 184 | 0.110 |
Why?
|
Erythropoiesis | 1 | 2013 | 51 | 0.110 |
Why?
|
Comorbidity | 1 | 2017 | 947 | 0.110 |
Why?
|
Imatinib Mesylate | 1 | 2013 | 127 | 0.110 |
Why?
|
Brain Neoplasms | 1 | 1999 | 779 | 0.110 |
Why?
|
Organic Anion Transporters, Sodium-Independent | 1 | 2013 | 5 | 0.110 |
Why?
|
Prevalence | 1 | 2017 | 1248 | 0.110 |
Why?
|
Pathology, Molecular | 1 | 2013 | 34 | 0.110 |
Why?
|
Axons | 1 | 2014 | 179 | 0.110 |
Why?
|
Leukemia, Prolymphocytic | 1 | 1992 | 3 | 0.110 |
Why?
|
Transfection | 4 | 2011 | 914 | 0.110 |
Why?
|
Health Policy | 1 | 2015 | 185 | 0.110 |
Why?
|
Off-Label Use | 1 | 2012 | 16 | 0.110 |
Why?
|
Adaptation, Physiological | 1 | 1995 | 316 | 0.110 |
Why?
|
Trastuzumab | 2 | 2023 | 70 | 0.110 |
Why?
|
Leukemia, B-Cell | 1 | 1992 | 23 | 0.110 |
Why?
|
Nicotine | 1 | 2014 | 199 | 0.110 |
Why?
|
Citrus paradisi | 1 | 2012 | 5 | 0.110 |
Why?
|
Conserved Sequence | 1 | 2013 | 211 | 0.110 |
Why?
|
DNA Topoisomerases, Type II | 2 | 2009 | 21 | 0.110 |
Why?
|
Binding, Competitive | 2 | 2010 | 146 | 0.110 |
Why?
|
Androstenols | 1 | 2012 | 3 | 0.110 |
Why?
|
Skin Neoplasms | 5 | 2020 | 577 | 0.110 |
Why?
|
Quality of Life | 5 | 2020 | 1649 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2011 | 865 | 0.100 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1992 | 14 | 0.100 |
Why?
|
Multifactorial Inheritance | 1 | 2014 | 167 | 0.100 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2017 | 123 | 0.100 |
Why?
|
Orchiectomy | 1 | 2012 | 72 | 0.100 |
Why?
|
Cells, Cultured | 3 | 2020 | 2879 | 0.100 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 158 | 0.100 |
Why?
|
Gene Dosage | 2 | 2013 | 208 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2012 | 93 | 0.100 |
Why?
|
Hydroxylation | 2 | 2009 | 17 | 0.100 |
Why?
|
Logistic Models | 4 | 1999 | 1205 | 0.100 |
Why?
|
Soft Tissue Neoplasms | 2 | 2009 | 129 | 0.100 |
Why?
|
Postmenopause | 1 | 2012 | 101 | 0.100 |
Why?
|
Students | 1 | 2013 | 163 | 0.100 |
Why?
|
Phosphorylation | 2 | 2018 | 1129 | 0.100 |
Why?
|
Therapeutic Equivalency | 2 | 2021 | 12 | 0.100 |
Why?
|
Anticoagulants | 2 | 2019 | 423 | 0.100 |
Why?
|
Peptides | 1 | 2015 | 646 | 0.100 |
Why?
|
Hemoglobins | 2 | 1991 | 189 | 0.100 |
Why?
|
Pentostatin | 7 | 2002 | 30 | 0.100 |
Why?
|
Rats | 5 | 2013 | 4041 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2011 | 22 | 0.100 |
Why?
|
Patient Care | 1 | 2012 | 101 | 0.100 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2008 | 697 | 0.100 |
Why?
|
Fibroblasts | 1 | 2014 | 755 | 0.100 |
Why?
|
Thalidomide | 1 | 2011 | 57 | 0.100 |
Why?
|
Adenoma | 1 | 2013 | 243 | 0.100 |
Why?
|
Androstadienes | 1 | 2011 | 72 | 0.100 |
Why?
|
Cyclosporins | 1 | 1991 | 58 | 0.100 |
Why?
|
Verapamil | 1 | 1991 | 34 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 891 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2012 | 171 | 0.100 |
Why?
|
Multivariate Analysis | 5 | 2009 | 995 | 0.100 |
Why?
|
Tumor Cells, Cultured | 4 | 2002 | 1057 | 0.100 |
Why?
|
Maryland | 1 | 2011 | 42 | 0.100 |
Why?
|
Life Expectancy | 1 | 2011 | 87 | 0.100 |
Why?
|
Pharmacoepidemiology | 1 | 2010 | 6 | 0.090 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2011 | 47 | 0.090 |
Why?
|
Acetaminophen | 1 | 2011 | 55 | 0.090 |
Why?
|
Gene Frequency | 4 | 2008 | 684 | 0.090 |
Why?
|
Thyroxine | 2 | 2015 | 347 | 0.090 |
Why?
|
Predictive Value of Tests | 5 | 2021 | 1709 | 0.090 |
Why?
|
DNA Repair | 2 | 2003 | 359 | 0.090 |
Why?
|
Insurance, Health | 1 | 2012 | 160 | 0.090 |
Why?
|
Feasibility Studies | 5 | 2004 | 774 | 0.090 |
Why?
|
Amino Acid Substitution | 1 | 2011 | 338 | 0.090 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 2 | 2009 | 80 | 0.090 |
Why?
|
Cholestasis | 1 | 1990 | 47 | 0.090 |
Why?
|
Microtubules | 2 | 2004 | 121 | 0.090 |
Why?
|
Healthcare Disparities | 1 | 2015 | 396 | 0.090 |
Why?
|
Efficiency | 1 | 2010 | 40 | 0.090 |
Why?
|
Cardiovascular Diseases | 2 | 2015 | 707 | 0.090 |
Why?
|
Smoking | 1 | 2014 | 618 | 0.090 |
Why?
|
Glycosylation | 1 | 2010 | 129 | 0.090 |
Why?
|
Burkitt Lymphoma | 1 | 2010 | 32 | 0.090 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 77 | 0.090 |
Why?
|
Electroencephalography | 1 | 1995 | 741 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2013 | 146 | 0.090 |
Why?
|
Half-Life | 5 | 2008 | 96 | 0.090 |
Why?
|
Indinavir | 2 | 2010 | 3 | 0.090 |
Why?
|
Daunorubicin | 2 | 2008 | 78 | 0.090 |
Why?
|
History, 21st Century | 1 | 2011 | 177 | 0.090 |
Why?
|
Vomiting | 4 | 2014 | 193 | 0.090 |
Why?
|
Severity of Illness Index | 3 | 2020 | 1843 | 0.090 |
Why?
|
Rituximab | 1 | 2010 | 119 | 0.090 |
Why?
|
Cell Cycle Proteins | 2 | 2010 | 399 | 0.090 |
Why?
|
Software | 2 | 2017 | 663 | 0.090 |
Why?
|
Kidney Function Tests | 2 | 2007 | 114 | 0.090 |
Why?
|
Motivation | 4 | 2012 | 295 | 0.090 |
Why?
|
Publishing | 1 | 2010 | 91 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2016 | 1647 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2016 | 1214 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2010 | 105 | 0.080 |
Why?
|
International Normalized Ratio | 1 | 2009 | 39 | 0.080 |
Why?
|
Mucositis | 1 | 2009 | 18 | 0.080 |
Why?
|
Podophyllotoxin | 3 | 1994 | 10 | 0.080 |
Why?
|
Pain | 2 | 2022 | 401 | 0.080 |
Why?
|
Blood Cell Count | 6 | 1999 | 79 | 0.080 |
Why?
|
Polymerase Chain Reaction | 2 | 2013 | 927 | 0.080 |
Why?
|
Topoisomerase Inhibitors | 1 | 2008 | 2 | 0.080 |
Why?
|
RecQ Helicases | 1 | 2008 | 7 | 0.080 |
Why?
|
Forecasting | 2 | 2008 | 305 | 0.080 |
Why?
|
Acute Disease | 4 | 2014 | 838 | 0.080 |
Why?
|
Werner Syndrome | 1 | 2008 | 2 | 0.080 |
Why?
|
Genes, Neoplasm | 1 | 2008 | 37 | 0.080 |
Why?
|
Pilot Projects | 4 | 2019 | 866 | 0.080 |
Why?
|
Platinum Compounds | 1 | 2008 | 31 | 0.080 |
Why?
|
Exodeoxyribonucleases | 1 | 2008 | 16 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 4 | 1998 | 565 | 0.080 |
Why?
|
Developed Countries | 1 | 2008 | 24 | 0.080 |
Why?
|
Health Care Sector | 1 | 2008 | 13 | 0.080 |
Why?
|
Enterohepatic Circulation | 1 | 2008 | 3 | 0.080 |
Why?
|
Hep G2 Cells | 3 | 2013 | 48 | 0.080 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 566 | 0.080 |
Why?
|
Personal Autonomy | 4 | 1998 | 116 | 0.080 |
Why?
|
MicroRNAs | 1 | 2013 | 551 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2008 | 74 | 0.080 |
Why?
|
Injections, Subcutaneous | 3 | 2004 | 119 | 0.080 |
Why?
|
Stereoisomerism | 3 | 2008 | 102 | 0.080 |
Why?
|
Immunotoxins | 2 | 1998 | 14 | 0.080 |
Why?
|
Lymphoma, Follicular | 1 | 2008 | 73 | 0.080 |
Why?
|
Economics, Medical | 1 | 2007 | 6 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 2638 | 0.080 |
Why?
|
MAP Kinase Signaling System | 1 | 2008 | 197 | 0.080 |
Why?
|
Carmustine | 2 | 2000 | 70 | 0.070 |
Why?
|
Phosphoproteins | 1 | 2009 | 260 | 0.070 |
Why?
|
Receptor, ErbB-2 | 2 | 2014 | 237 | 0.070 |
Why?
|
Everolimus | 1 | 2007 | 42 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2014 | 884 | 0.070 |
Why?
|
Gene Amplification | 1 | 2007 | 133 | 0.070 |
Why?
|
Hypotension | 3 | 2004 | 70 | 0.070 |
Why?
|
Insurance | 1 | 2007 | 12 | 0.070 |
Why?
|
Evolution, Molecular | 1 | 2013 | 836 | 0.070 |
Why?
|
Age Factors | 4 | 2014 | 1863 | 0.070 |
Why?
|
Tissue Distribution | 2 | 2021 | 292 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2008 | 181 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 157 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2010 | 354 | 0.070 |
Why?
|
Base Sequence | 3 | 2008 | 2331 | 0.070 |
Why?
|
Employment | 1 | 2007 | 53 | 0.070 |
Why?
|
Immunoenzyme Techniques | 2 | 2002 | 306 | 0.070 |
Why?
|
Observer Variation | 1 | 2008 | 609 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2009 | 311 | 0.070 |
Why?
|
Radiotherapy | 2 | 2003 | 331 | 0.070 |
Why?
|
Medication Errors | 1 | 2007 | 39 | 0.070 |
Why?
|
Nogalamycin | 1 | 1986 | 2 | 0.070 |
Why?
|
Serum Albumin | 3 | 1995 | 128 | 0.070 |
Why?
|
Tea | 1 | 2006 | 21 | 0.070 |
Why?
|
Molecular Structure | 1 | 2007 | 289 | 0.070 |
Why?
|
Patient Reported Outcome Measures | 2 | 2019 | 190 | 0.070 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 154 | 0.070 |
Why?
|
Thymidine | 1 | 1986 | 60 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2011 | 390 | 0.070 |
Why?
|
Catechin | 1 | 2006 | 24 | 0.070 |
Why?
|
Photosensitivity Disorders | 1 | 2006 | 16 | 0.070 |
Why?
|
Structure-Activity Relationship | 1 | 2007 | 411 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2020 | 1851 | 0.070 |
Why?
|
Keratosis | 1 | 2006 | 21 | 0.070 |
Why?
|
Complementary Therapies | 1 | 2007 | 56 | 0.070 |
Why?
|
Probability | 1 | 2007 | 356 | 0.070 |
Why?
|
Infusion Pumps | 5 | 1989 | 25 | 0.070 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2006 | 24 | 0.070 |
Why?
|
Asthma | 1 | 2014 | 973 | 0.070 |
Why?
|
Drug Combinations | 3 | 2010 | 203 | 0.070 |
Why?
|
Genes, ras | 1 | 2006 | 98 | 0.070 |
Why?
|
Molecular Sequence Data | 3 | 2008 | 3029 | 0.070 |
Why?
|
Retrospective Studies | 8 | 2013 | 8893 | 0.070 |
Why?
|
Patients | 1 | 2007 | 102 | 0.070 |
Why?
|
Mice | 6 | 2016 | 11710 | 0.070 |
Why?
|
Foot Dermatoses | 1 | 1985 | 3 | 0.070 |
Why?
|
Rats, Wistar | 2 | 1997 | 302 | 0.070 |
Why?
|
Protein Structure, Tertiary | 1 | 2007 | 741 | 0.070 |
Why?
|
Hand Dermatoses | 1 | 1985 | 9 | 0.070 |
Why?
|
Neutrophils | 3 | 2002 | 308 | 0.070 |
Why?
|
Adsorption | 1 | 2005 | 54 | 0.060 |
Why?
|
Alternative Splicing | 2 | 2008 | 210 | 0.060 |
Why?
|
Furans | 1 | 2005 | 16 | 0.060 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2005 | 127 | 0.060 |
Why?
|
Consensus Sequence | 1 | 2005 | 65 | 0.060 |
Why?
|
Filgrastim | 2 | 2003 | 57 | 0.060 |
Why?
|
Phenylenediamines | 1 | 2004 | 6 | 0.060 |
Why?
|
Thiophenes | 3 | 2000 | 43 | 0.060 |
Why?
|
Meperidine | 1 | 2004 | 13 | 0.060 |
Why?
|
Injections, Intravenous | 3 | 2004 | 241 | 0.060 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2004 | 14 | 0.060 |
Why?
|
Cytochrome P-450 Enzyme Inhibitors | 1 | 2004 | 10 | 0.060 |
Why?
|
Drug Hypersensitivity | 1 | 2004 | 37 | 0.060 |
Why?
|
Capsules | 1 | 2004 | 38 | 0.060 |
Why?
|
Transaminases | 1 | 2004 | 33 | 0.060 |
Why?
|
Quinolones | 1 | 2004 | 60 | 0.060 |
Why?
|
In Vitro Techniques | 3 | 2015 | 995 | 0.060 |
Why?
|
B-Lymphocytes | 2 | 2008 | 737 | 0.060 |
Why?
|
Mixed Function Oxygenases | 1 | 2004 | 69 | 0.060 |
Why?
|
Coformycin | 3 | 1989 | 9 | 0.060 |
Why?
|
Tissue Fixation | 2 | 2014 | 40 | 0.060 |
Why?
|
Gene Transfer Techniques | 1 | 2004 | 153 | 0.060 |
Why?
|
Paraffin Embedding | 2 | 2014 | 78 | 0.060 |
Why?
|
Formaldehyde | 2 | 2014 | 52 | 0.060 |
Why?
|
Neoplasm Transplantation | 1 | 2004 | 397 | 0.060 |
Why?
|
Pyrrolidines | 1 | 2004 | 59 | 0.060 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2010 | 78 | 0.060 |
Why?
|
Research Support as Topic | 1 | 2004 | 82 | 0.060 |
Why?
|
Greenhouse Effect | 1 | 2023 | 2 | 0.060 |
Why?
|
Ethics, Research | 1 | 2004 | 52 | 0.060 |
Why?
|
Mouth Mucosa | 2 | 2014 | 67 | 0.060 |
Why?
|
Idoxuridine | 2 | 1993 | 16 | 0.060 |
Why?
|
Pelvis | 1 | 2003 | 94 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2004 | 130 | 0.060 |
Why?
|
Alkaline Phosphatase | 4 | 2002 | 133 | 0.060 |
Why?
|
CD56 Antigen | 1 | 2002 | 18 | 0.050 |
Why?
|
Chromium | 1 | 2002 | 17 | 0.050 |
Why?
|
Endostatins | 1 | 2002 | 6 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 3678 | 0.050 |
Why?
|
Therapies, Investigational | 1 | 2022 | 17 | 0.050 |
Why?
|
Pharmacists | 1 | 2022 | 32 | 0.050 |
Why?
|
CHO Cells | 1 | 2002 | 187 | 0.050 |
Why?
|
Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
Hepatitis C | 1 | 2005 | 219 | 0.050 |
Why?
|
Syndrome | 1 | 2003 | 448 | 0.050 |
Why?
|
Hydralazine | 1 | 2022 | 19 | 0.050 |
Why?
|
Morphine | 1 | 2003 | 130 | 0.050 |
Why?
|
Protein Kinase C-alpha | 1 | 2002 | 27 | 0.050 |
Why?
|
Epoprostenol | 1 | 2022 | 46 | 0.050 |
Why?
|
X-ray Repair Cross Complementing Protein 1 | 1 | 2021 | 2 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2002 | 275 | 0.050 |
Why?
|
Population | 1 | 2002 | 35 | 0.050 |
Why?
|
Familial Primary Pulmonary Hypertension | 1 | 2022 | 60 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2002 | 691 | 0.050 |
Why?
|
Immunohistochemistry | 2 | 2004 | 1790 | 0.050 |
Why?
|
Oxycodone | 1 | 2022 | 35 | 0.050 |
Why?
|
Anorexia | 1 | 2001 | 30 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2002 | 92 | 0.050 |
Why?
|
Cricetinae | 1 | 2002 | 560 | 0.050 |
Why?
|
Point Mutation | 1 | 2002 | 246 | 0.050 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2024 | 237 | 0.050 |
Why?
|
Carbon Radioisotopes | 1 | 2001 | 35 | 0.050 |
Why?
|
Interinstitutional Relations | 1 | 2001 | 29 | 0.050 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.050 |
Why?
|
Anthropometry | 1 | 2001 | 76 | 0.050 |
Why?
|
Data Collection | 2 | 2000 | 374 | 0.050 |
Why?
|
Complement System Proteins | 1 | 2001 | 83 | 0.050 |
Why?
|
Cardiac Output | 1 | 2001 | 156 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2008 | 2346 | 0.050 |
Why?
|
Blood Coagulation | 1 | 2001 | 92 | 0.050 |
Why?
|
Neurites | 1 | 2020 | 36 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 863 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2014 | 1051 | 0.050 |
Why?
|
Aspartate Aminotransferases | 1 | 2000 | 74 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.050 |
Why?
|
Carcinoma | 1 | 2004 | 441 | 0.050 |
Why?
|
Proprotein Convertase 9 | 1 | 2020 | 20 | 0.040 |
Why?
|
Lactones | 1 | 2000 | 27 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 270 | 0.040 |
Why?
|
Macrolides | 1 | 2000 | 31 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 244 | 0.040 |
Why?
|
Interferons | 4 | 1990 | 134 | 0.040 |
Why?
|
Glutathione | 2 | 2000 | 109 | 0.040 |
Why?
|
Administration, Intravenous | 1 | 2019 | 51 | 0.040 |
Why?
|
Colonic Polyps | 1 | 2000 | 130 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2001 | 365 | 0.040 |
Why?
|
Gene Expression | 2 | 2014 | 1312 | 0.040 |
Why?
|
Hypoxia | 1 | 2004 | 650 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2004 | 902 | 0.040 |
Why?
|
Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
Codeine | 1 | 2019 | 12 | 0.040 |
Why?
|
Myosin Type II | 1 | 2019 | 50 | 0.040 |
Why?
|
Hypolipidemic Agents | 1 | 2020 | 99 | 0.040 |
Why?
|
Myosin Heavy Chains | 1 | 2019 | 92 | 0.040 |
Why?
|
Feces | 1 | 2001 | 326 | 0.040 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 127 | 0.040 |
Why?
|
Hospitalization | 2 | 2019 | 871 | 0.040 |
Why?
|
Aldehyde Dehydrogenase | 1 | 1998 | 15 | 0.040 |
Why?
|
NFATC Transcription Factors | 1 | 2018 | 49 | 0.040 |
Why?
|
Hematologic Diseases | 2 | 1996 | 78 | 0.040 |
Why?
|
Alkyl and Aryl Transferases | 1 | 1998 | 15 | 0.040 |
Why?
|
Ribonucleosides | 2 | 1989 | 25 | 0.040 |
Why?
|
Organic Anion Transporters | 2 | 2009 | 26 | 0.040 |
Why?
|
Crigler-Najjar Syndrome | 1 | 1998 | 3 | 0.040 |
Why?
|
Mycosis Fungoides | 1 | 1998 | 29 | 0.040 |
Why?
|
Zidovudine | 1 | 1998 | 16 | 0.040 |
Why?
|
Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 5 | 0.040 |
Why?
|
Nitrophenols | 1 | 1998 | 11 | 0.040 |
Why?
|
Anticonvulsants | 1 | 1999 | 125 | 0.040 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2018 | 68 | 0.040 |
Why?
|
Program Evaluation | 1 | 2019 | 303 | 0.040 |
Why?
|
Treatment Refusal | 1 | 1998 | 62 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 342 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 478 | 0.040 |
Why?
|
Exons | 2 | 2011 | 452 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
Causality | 1 | 1998 | 80 | 0.040 |
Why?
|
Infant | 2 | 2020 | 3117 | 0.040 |
Why?
|
Cancer Survivors | 1 | 2019 | 94 | 0.040 |
Why?
|
Alcohol Dehydrogenase | 1 | 1997 | 42 | 0.040 |
Why?
|
DNA Methylation | 1 | 2002 | 656 | 0.040 |
Why?
|
Consent Forms | 2 | 1995 | 11 | 0.040 |
Why?
|
Vinca Alkaloids | 1 | 1997 | 3 | 0.040 |
Why?
|
Cosyntropin | 1 | 1996 | 5 | 0.040 |
Why?
|
Multicenter Studies as Topic | 2 | 2015 | 156 | 0.040 |
Why?
|
Isotretinoin | 1 | 1997 | 23 | 0.040 |
Why?
|
Pain, Postoperative | 1 | 2019 | 248 | 0.040 |
Why?
|
Thiotepa | 2 | 2004 | 32 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 471 | 0.040 |
Why?
|
Aldosterone | 1 | 1996 | 56 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2000 | 460 | 0.040 |
Why?
|
Health Personnel | 1 | 2019 | 209 | 0.030 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1996 | 131 | 0.030 |
Why?
|
Tetrahydrofolates | 1 | 1996 | 13 | 0.030 |
Why?
|
Disease Management | 1 | 2019 | 328 | 0.030 |
Why?
|
Morphine Derivatives | 2 | 2008 | 8 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2019 | 381 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2018 | 367 | 0.030 |
Why?
|
User-Computer Interface | 1 | 2017 | 187 | 0.030 |
Why?
|
Social Perception | 1 | 2017 | 96 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2008 | 3445 | 0.030 |
Why?
|
Antigens, Neoplasm | 2 | 2009 | 330 | 0.030 |
Why?
|
Keratoacanthoma | 1 | 1996 | 4 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 507 | 0.030 |
Why?
|
Mitoxantrone | 1 | 1996 | 68 | 0.030 |
Why?
|
Biological Transport | 2 | 2002 | 400 | 0.030 |
Why?
|
Vitamin D | 1 | 2018 | 267 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 499 | 0.030 |
Why?
|
Digestive System Diseases | 1 | 1996 | 18 | 0.030 |
Why?
|
Life Tables | 1 | 1995 | 48 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2016 | 101 | 0.030 |
Why?
|
Quality Control | 1 | 2016 | 116 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2016 | 290 | 0.030 |
Why?
|
Bleomycin | 2 | 1993 | 102 | 0.030 |
Why?
|
Microsomes | 1 | 2015 | 35 | 0.030 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 169 | 0.030 |
Why?
|
Transcription Factors | 2 | 2014 | 1647 | 0.030 |
Why?
|
Communication | 1 | 2019 | 452 | 0.030 |
Why?
|
Interferon-gamma | 2 | 1988 | 452 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 1996 | 360 | 0.030 |
Why?
|
Lung | 2 | 2014 | 1243 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
Bias | 2 | 1995 | 130 | 0.030 |
Why?
|
Blast Crisis | 1 | 1995 | 36 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 1998 | 1237 | 0.030 |
Why?
|
Chromatography, Liquid | 2 | 2010 | 106 | 0.030 |
Why?
|
Chromosome Mapping | 2 | 2011 | 1077 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 1996 | 143 | 0.030 |
Why?
|
Coma | 1 | 1995 | 45 | 0.030 |
Why?
|
Linear Models | 1 | 1996 | 423 | 0.030 |
Why?
|
Blotting, Western | 2 | 2008 | 797 | 0.030 |
Why?
|
Body Mass Index | 1 | 1998 | 770 | 0.030 |
Why?
|
Peroxisome-Targeting Signal 1 Receptor | 1 | 2014 | 3 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 80 | 0.030 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 36 | 0.030 |
Why?
|
Tumor Burden | 1 | 2016 | 304 | 0.030 |
Why?
|
Budesonide | 1 | 2014 | 46 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 1995 | 157 | 0.030 |
Why?
|
Antineoplastic Protocols | 1 | 2014 | 9 | 0.030 |
Why?
|
Prostatectomy | 1 | 2018 | 476 | 0.030 |
Why?
|
Blindness | 1 | 1994 | 40 | 0.030 |
Why?
|
Lymphocytes | 3 | 2004 | 470 | 0.030 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 1994 | 18 | 0.030 |
Why?
|
Prostate | 1 | 2018 | 392 | 0.030 |
Why?
|
Cell Line | 2 | 2010 | 2498 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2016 | 386 | 0.030 |
Why?
|
DNA, Complementary | 2 | 2007 | 392 | 0.030 |
Why?
|
Reference Standards | 1 | 2014 | 143 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2017 | 340 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2013 | 22 | 0.030 |
Why?
|
Body Height | 1 | 2014 | 100 | 0.030 |
Why?
|
Arylsulfotransferase | 1 | 2013 | 4 | 0.030 |
Why?
|
Clonal Evolution | 1 | 2013 | 15 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
Blood Platelets | 1 | 1994 | 150 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2008 | 858 | 0.030 |
Why?
|
Dacarbazine | 1 | 1994 | 102 | 0.030 |
Why?
|
Odds Ratio | 1 | 2015 | 686 | 0.030 |
Why?
|
Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2013 | 4 | 0.030 |
Why?
|
Drug Stability | 1 | 2013 | 48 | 0.030 |
Why?
|
Anthracenes | 1 | 1993 | 16 | 0.030 |
Why?
|
Astrocytoma | 1 | 1993 | 82 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2014 | 177 | 0.030 |
Why?
|
Regulatory Factor X Transcription Factors | 1 | 2012 | 12 | 0.030 |
Why?
|
Frozen Sections | 1 | 2013 | 49 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 64 | 0.030 |
Why?
|
Ethical Review | 1 | 1992 | 8 | 0.030 |
Why?
|
Cattle | 1 | 2013 | 375 | 0.030 |
Why?
|
Blood | 1 | 1993 | 69 | 0.030 |
Why?
|
Receptor, EphA5 | 1 | 2012 | 2 | 0.030 |
Why?
|
Blood Transfusion | 2 | 1991 | 164 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2012 | 46 | 0.030 |
Why?
|
Imidazoles | 1 | 2013 | 151 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 846 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2013 | 109 | 0.030 |
Why?
|
Dogs | 1 | 2013 | 704 | 0.030 |
Why?
|
Sepsis | 1 | 1996 | 317 | 0.030 |
Why?
|
ras Proteins | 1 | 2013 | 130 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1992 | 54 | 0.030 |
Why?
|
Insurance Benefits | 1 | 2012 | 8 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1992 | 106 | 0.030 |
Why?
|
Up-Regulation | 1 | 2014 | 729 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 1991 | 48 | 0.030 |
Why?
|
Intellectual Property | 1 | 2011 | 3 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 499 | 0.020 |
Why?
|
Monocytes | 3 | 1994 | 217 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2012 | 45 | 0.020 |
Why?
|
Species Specificity | 1 | 2013 | 685 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 531 | 0.020 |
Why?
|
Pan troglodytes | 1 | 2013 | 199 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 53 | 0.020 |
Why?
|
Carcinoma, Merkel Cell | 1 | 1991 | 17 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2011 | 29 | 0.020 |
Why?
|
Taiwan | 1 | 2011 | 23 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2016 | 1988 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2011 | 62 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 1992 | 266 | 0.020 |
Why?
|
Allelic Imbalance | 1 | 2011 | 22 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2011 | 95 | 0.020 |
Why?
|
Genetic Loci | 1 | 2012 | 253 | 0.020 |
Why?
|
Public Sector | 1 | 2010 | 12 | 0.020 |
Why?
|
Glioblastoma | 1 | 1993 | 265 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2013 | 465 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2012 | 212 | 0.020 |
Why?
|
Toxicity Tests | 1 | 2010 | 13 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2011 | 160 | 0.020 |
Why?
|
Receptors, Growth Factor | 1 | 2010 | 52 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 2 | 2002 | 42 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 502 | 0.020 |
Why?
|
Antibody Formation | 1 | 1991 | 171 | 0.020 |
Why?
|
Hymecromone | 1 | 2010 | 4 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2010 | 105 | 0.020 |
Why?
|
Glucuronic Acid | 1 | 2010 | 11 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2011 | 647 | 0.020 |
Why?
|
Imipramine | 1 | 2010 | 16 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 146 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2010 | 131 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2015 | 804 | 0.020 |
Why?
|
Biocatalysis | 1 | 2010 | 51 | 0.020 |
Why?
|
Gene Deletion | 1 | 2011 | 342 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2011 | 446 | 0.020 |
Why?
|
Aging | 1 | 1994 | 712 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1484 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 183 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2010 | 179 | 0.020 |
Why?
|
Demography | 1 | 2009 | 181 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 3202 | 0.020 |
Why?
|
Leukemia L1210 | 1 | 1988 | 12 | 0.020 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2009 | 66 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2010 | 200 | 0.020 |
Why?
|
Melphalan | 1 | 1989 | 98 | 0.020 |
Why?
|
Werner Syndrome Helicase | 1 | 2008 | 2 | 0.020 |
Why?
|
Survivors | 1 | 2010 | 233 | 0.020 |
Why?
|
Osteolysis | 1 | 1988 | 14 | 0.020 |
Why?
|
Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
Thiones | 2 | 2000 | 10 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 95 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 2019 | 0.020 |
Why?
|
Rats, Inbred Dahl | 1 | 2008 | 8 | 0.020 |
Why?
|
Complement C1q | 1 | 2008 | 11 | 0.020 |
Why?
|
Transforming Growth Factor beta3 | 1 | 2008 | 16 | 0.020 |
Why?
|
Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1989 | 283 | 0.020 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2008 | 33 | 0.020 |
Why?
|
Recurrence | 2 | 2008 | 1168 | 0.020 |
Why?
|
Incidence | 1 | 2012 | 1592 | 0.020 |
Why?
|
Luciferases, Firefly | 1 | 2007 | 12 | 0.020 |
Why?
|
Karyotyping | 1 | 1987 | 253 | 0.020 |
Why?
|
Xenobiotics | 1 | 2007 | 7 | 0.020 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 1998 | 28 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 2008 | 264 | 0.020 |
Why?
|
Informatics | 1 | 2007 | 5 | 0.020 |
Why?
|
Cytarabine | 1 | 2008 | 219 | 0.020 |
Why?
|
Herb-Drug Interactions | 1 | 2007 | 4 | 0.020 |
Why?
|
Antigens, Surface | 1 | 1987 | 103 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2007 | 88 | 0.020 |
Why?
|
Aerosols | 1 | 2007 | 44 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 1987 | 47 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2007 | 73 | 0.020 |
Why?
|
Hydroxytestosterones | 1 | 2006 | 1 | 0.020 |
Why?
|
Plant Preparations | 1 | 2007 | 20 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2008 | 226 | 0.020 |
Why?
|
Pharmacokinetics | 1 | 2006 | 10 | 0.020 |
Why?
|
Menogaril | 1 | 1986 | 3 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2007 | 275 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 1986 | 51 | 0.020 |
Why?
|
Thymine | 1 | 1986 | 17 | 0.020 |
Why?
|
Digestive System | 1 | 1986 | 42 | 0.020 |
Why?
|
Hyponatremia | 1 | 1986 | 27 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2007 | 188 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1989 | 294 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2008 | 698 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2011 | 418 | 0.020 |
Why?
|
Empirical Research | 2 | 1997 | 19 | 0.020 |
Why?
|
Vitamins | 1 | 2007 | 82 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2007 | 130 | 0.020 |
Why?
|
Cell Survival | 1 | 2008 | 980 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 142 | 0.020 |
Why?
|
Mephenytoin | 1 | 2004 | 2 | 0.020 |
Why?
|
Cytochrome P-450 CYP2B6 | 1 | 2004 | 6 | 0.020 |
Why?
|
Fluvoxamine | 1 | 2004 | 7 | 0.020 |
Why?
|
Receptors, Endothelin | 1 | 2004 | 12 | 0.020 |
Why?
|
Lung Diseases | 1 | 2007 | 269 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2005 | 205 | 0.020 |
Why?
|
Hemodynamics | 1 | 2008 | 728 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 307 | 0.010 |
Why?
|
Vincristine | 2 | 1997 | 112 | 0.010 |
Why?
|
Analgesia, Patient-Controlled | 1 | 2003 | 16 | 0.010 |
Why?
|
Indicators and Reagents | 1 | 2003 | 72 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2007 | 679 | 0.010 |
Why?
|
Contrast Media | 1 | 2008 | 1088 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2007 | 409 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2008 | 779 | 0.010 |
Why?
|
Risk | 1 | 2004 | 660 | 0.010 |
Why?
|
Dexamethasone | 1 | 2004 | 344 | 0.010 |
Why?
|
Propofol | 1 | 2002 | 91 | 0.010 |
Why?
|
Global Health | 1 | 2002 | 186 | 0.010 |
Why?
|
Catalysis | 1 | 2001 | 205 | 0.010 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2000 | 43 | 0.010 |
Why?
|
Hot Temperature | 1 | 2000 | 208 | 0.010 |
Why?
|
Rectum | 1 | 2000 | 148 | 0.010 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 1998 | 44 | 0.010 |
Why?
|
Shivering | 1 | 1998 | 4 | 0.010 |
Why?
|
Dermatitis, Exfoliative | 1 | 1998 | 3 | 0.010 |
Why?
|
Methotrexate | 2 | 1989 | 250 | 0.010 |
Why?
|
Pentoxifylline | 1 | 1998 | 9 | 0.010 |
Why?
|
Platelet Count | 2 | 1989 | 93 | 0.010 |
Why?
|
Cell Count | 1 | 1998 | 199 | 0.010 |
Why?
|
Neoplasms, Experimental | 1 | 1999 | 269 | 0.010 |
Why?
|
Persons | 1 | 1997 | 6 | 0.010 |
Why?
|
Control Groups | 1 | 1997 | 15 | 0.010 |
Why?
|
Federal Government | 1 | 1997 | 29 | 0.010 |
Why?
|
Paternalism | 1 | 1997 | 24 | 0.010 |
Why?
|
Vasodilator Agents | 1 | 1998 | 146 | 0.010 |
Why?
|
Chromatography, Ion Exchange | 1 | 1997 | 34 | 0.010 |
Why?
|
Patient Advocacy | 1 | 1997 | 52 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1997 | 80 | 0.010 |
Why?
|
Radiography | 1 | 1999 | 807 | 0.010 |
Why?
|
Vulnerable Populations | 1 | 1997 | 80 | 0.010 |
Why?
|
Ligands | 1 | 1998 | 440 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 1998 | 575 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 1997 | 193 | 0.010 |
Why?
|
Brain | 1 | 1986 | 2268 | 0.010 |
Why?
|
Enzyme Induction | 1 | 1995 | 88 | 0.010 |
Why?
|
Karnofsky Performance Status | 1 | 1995 | 40 | 0.010 |
Why?
|
Menopause | 1 | 1995 | 76 | 0.010 |
Why?
|
Catheterization, Central Venous | 1 | 1996 | 115 | 0.010 |
Why?
|
CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
Cultural Diversity | 1 | 1995 | 53 | 0.010 |
Why?
|
Educational Status | 1 | 1995 | 191 | 0.010 |
Why?
|
Truth Disclosure | 1 | 1995 | 91 | 0.010 |
Why?
|
Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 1994 | 66 | 0.010 |
Why?
|
Benzofurans | 1 | 1994 | 9 | 0.010 |
Why?
|
Trust | 1 | 1995 | 97 | 0.010 |
Why?
|
Professional Staff Committees | 1 | 1992 | 7 | 0.010 |
Why?
|
Cancer Care Facilities | 1 | 1992 | 29 | 0.010 |
Why?
|
Hemoglobin A | 1 | 1992 | 8 | 0.010 |
Why?
|
2-Chloroadenosine | 1 | 1992 | 5 | 0.010 |
Why?
|
Deoxyadenosines | 1 | 1992 | 23 | 0.010 |
Why?
|
Platinum | 1 | 1992 | 63 | 0.010 |
Why?
|
Diabetes Complications | 1 | 1993 | 172 | 0.010 |
Why?
|
Respiratory Insufficiency | 1 | 1993 | 159 | 0.010 |
Why?
|
Electrocardiography | 1 | 1993 | 495 | 0.010 |
Why?
|
Absorption | 1 | 1989 | 25 | 0.010 |
Why?
|
Acid Phosphatase | 1 | 1988 | 34 | 0.010 |
Why?
|
Chlorambucil | 1 | 1988 | 23 | 0.010 |
Why?
|
Chromatography, Gas | 1 | 1988 | 28 | 0.010 |
Why?
|
|